^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Trodelvy (sacituzumab govitecan-hziy)

    i
    Other names: IMMU-132, IMMU132, IMMU 132, hRS7-SN38 antibody drug conjugate, hRS7-SN 38, anti-TROP-2-SN-38 conjugate, anti-TROP-2-SN-38, hRS7-CL2-SN-38, IMMU0132, GS-0132, RS7-SN38, hMN14-SN38, TROP-2-SN-38
    Company:
    Gilead
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    Apply
    A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)
    A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung) (NCT03337698)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/27/2017
    Primary completion :
    09/30/2025
    Completion :
    11/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (NCT06081244)
    Phase 2
    West German Study Group
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/10/2024
    Primary completion :
    09/01/2029
    Completion :
    09/01/2029
    HER-2 • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (Morpheus-TNBC) (NCT03424005)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    03/30/2018
    Primary completion :
    05/03/2028
    Completion :
    05/03/2028
    HER-2 • PD-L1 • PIK3CA
    |
    PD-L1 expression • PIK3CA mutation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (NCI-2018-01581) (NCT03606967)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    04/13/2021
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    HER-2 • PD-L1 • ER • PGR • CD4
    |
    PD-L1 expression • HER-2 negative • PD-L1 negative
    |
    carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab-actl) • Trodelvy (sacituzumab govitecan-hziy) • Hiltonol (poly-ICLC) • liposomal gemcitabine (FF-10832)
    Study of AVZO-021 in Patients with Advanced Solid Tumors (ARTS-021-1001) (NCT05867251)
    Phase 1/2
    Avenzo Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/30/2023
    Primary completion :
    01/31/2028
    Completion :
    01/31/2030
    HER-2 • CCNE1
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021
    Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) (NCT05633654)
    Phase 3
    Gilead Sciences
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    12/12/2022
    Primary completion :
    06/01/2027
    Completion :
    08/01/2031
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • capecitabine • Trodelvy (sacituzumab govitecan-hziy)
    Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (WIN-B) (NCT06612203)
    Phase 1/2
    MedSIR
    Recruiting
    Last update posted :
    01/24/2025
    Initiation :
    01/17/2025
    Primary completion :
    02/01/2027
    Completion :
    10/01/2027
    HER-2
    |
    HER-2 negative
    |
    Trodelvy (sacituzumab govitecan-hziy) • Debio 0123
    Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (MORPHEUS mUC) (NCT03869190)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    01/03/2025
    Initiation :
    06/01/2019
    Primary completion :
    10/03/2024
    Completion :
    05/21/2026
    PD-L1
    |
    cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827 • lomvastomig (RG7769)
    Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) (NCT05382286)
    Phase 3
    Gilead Sciences
    Active, not recruiting
    Last update posted :
    12/24/2024
    Initiation :
    07/25/2022
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    PD-L1
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)
    Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (NCT06739395)
    Phase 2
    Tianjin Medical University Second Hospital
    Recruiting
    Last update posted :
    12/18/2024
    Initiation :
    11/01/2024
    Primary completion :
    12/31/2026
    Completion :
    05/01/2027
    BRAF
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • bozitinib (APL-101)
    Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC (Saci-IO TNBC) (NCT04468061)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    09/19/2024
    Initiation :
    07/20/2020
    Primary completion :
    04/01/2026
    Completion :
    04/01/2029
    HER-2 • PD-L1 • ER • PGR
    |
    PD-L1 expression • HER-2 negative • PD-L1 negative
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC (Saci-IO HR+) (NCT04448886)
    Phase 2
    Ana C Garrido-Castro, MD
    Active, not recruiting
    Last update posted :
    09/10/2024
    Initiation :
    09/23/2020
    Primary completion :
    03/09/2024
    Completion :
    06/01/2027
    HER-2
    |
    HR positive • HER-2 negative
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (EVER-132-002) (NCT04639986)
    Phase 3
    Gilead Sciences
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    11/23/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)
    Study of Sacituzumab Govitecan in Patients With Solid Tumor (EVER-132-003) (NCT05119907)
    Phase 2
    Gilead Sciences
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    10/12/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    EGFR • BRAF • ALK • ROS1
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03) (NCT05382299)
    Phase 3
    Gilead Sciences
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    07/20/2022
    Primary completion :
    05/01/2027
    Completion :
    05/01/2027
    PD-L1
    |
    PD-L1 expression • PD-L1 negative
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)
    Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) (KEYNOTE D46) (NCT05609968)
    Phase 3
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    02/06/2023
    Primary completion :
    01/12/2027
    Completion :
    08/23/2028
    EGFR • PD-L1 • ALK • ROS1
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) (NCT05633667)
    Phase 2
    Gilead Sciences
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    03/16/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    EGFR • PD-L1 • ALK
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)
    Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01) (NCT05089734)
    Phase 3
    Gilead Sciences
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    11/17/2021
    Primary completion :
    11/29/2023
    Completion :
    03/01/2025
    EGFR • ALK
    |
    docetaxel • Trodelvy (sacituzumab govitecan-hziy)
    A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) (NCT06100874)
    Phase 2
    Adrienne G. Waks
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    11/20/2023
    Primary completion :
    11/30/2026
    Completion :
    11/30/2027
    HER-2
    |
    PGR expression
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE) (NCT05552001)
    Phase 3
    UNICANCER
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    10/05/2023
    Primary completion :
    12/01/2024
    Completion :
    05/01/2026
    HER-2 • ER • PGR • PD-1
    |
    ER expression • PGR expression • ER amplification • PD-1 positive
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) (NCT05840211)
    Phase 3
    Gilead Sciences
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    05/08/2023
    Primary completion :
    09/01/2025
    Completion :
    12/01/2028
    HER-2
    |
    HER-2 negative
    |
    capecitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)
    A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma (NCT04251416)
    Phase 2
    Yale University
    Recruiting
    Last update posted :
    05/24/2024
    Initiation :
    03/17/2020
    Primary completion :
    12/01/2024
    Completion :
    02/01/2026
    TACSTD2
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED (NCT05520723)
    Phase 2
    MedSIR
    Active, not recruiting
    Last update posted :
    05/15/2024
    Initiation :
    02/07/2023
    Primary completion :
    12/14/2025
    Completion :
    12/14/2025
    HER-2 • ER • PGR
    |
    ER expression
    |
    Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim)
    A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) (NCT05675579)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    05/23/2023
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • ER positive + PGR positive • PGR negative
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe) (NCT03971409)
    Phase 2
    Hope Rugo, MD
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    07/08/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative
    |
    Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)
    Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02) (NCT05101096)
    Phase 1/2
    Gilead Sciences
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    10/20/2021
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    HER-2
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion (NCT04794699)
    Phase 1
    IDEAYA Biosciences
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    04/14/2021
    Primary completion :
    12/31/2026
    Completion :
    03/30/2027
    MTAP
    |
    MTAP deletion
    |
    gemcitabine • paclitaxel • docetaxel • albumin-bound paclitaxel • pemetrexed • Trodelvy (sacituzumab govitecan-hziy) • IDE397
    Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma (NCT06123468)
    Phase 1/2
    Institut für Klinische Krebsforschung IKF GmbH ...
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    04/17/2024
    Primary completion :
    02/01/2027
    Completion :
    03/01/2027
    MSI
    |
    MSI-H/dMMR
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy (NCT06065371)
    Phase 1
    Henry Ford Health System
    Not yet recruiting
    Last update posted :
    04/19/2024
    Initiation :
    06/01/2024
    Primary completion :
    08/01/2025
    Completion :
    02/01/2026
    TACSTD2
    |
    capecitabine • Trodelvy (sacituzumab govitecan-hziy)
    Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. (NCT04039230)
    Phase 1/2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    10/09/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 negative • ER negative • PGR negative
    |
    Talzenna (talazoparib) • Trodelvy (sacituzumab govitecan-hziy)
    Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy (NCT05770531)
    Phase 2
    Vanderbilt-Ingram Cancer Center
    Suspended
    Last update posted :
    03/27/2024
    Initiation :
    10/02/2023
    Primary completion :
    10/01/2027
    Completion :
    10/01/2028
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative • PD-L1 negative
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma (SG-ESCC) (NCT06329869)
    Phase 2
    National Taiwan University Hospital
    Not yet recruiting
    Last update posted :
    03/26/2024
    Initiation :
    05/01/2024
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    TACSTD2
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Sacituzumab Govitecan In TNBC (NeoSTAR) (NCT04230109)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    07/14/2020
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 negative • ER negative • PGR negative
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC) (NCT04958785)
    Phase 2
    Gilead Sciences
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    12/14/2021
    Primary completion :
    08/01/2024
    Completion :
    01/01/2025
    PD-L1
    |
    PD-L1 expression • PD-L1 negative
    |
    albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • magrolimab (ONO-7913)
    Sacituzumab Govitecan in Recurrent Glioblastoma (NCT04559230)
    Phase 2
    The University of Texas Health Science Center a...
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    01/06/2022
    Primary completion :
    08/01/2024
    Completion :
    02/01/2025
    MGMT
    |
    RAS wild-type • IDH wild-type
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments (EVER-132-001) (NCT04454437)
    Phase 2
    Gilead Sciences
    Active, not recruiting
    Last update posted :
    03/12/2024
    Initiation :
    10/23/2020
    Primary completion :
    08/06/2021
    Completion :
    12/01/2024
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer (NCT06055465)
    Phase 2
    Chinese University of Hong Kong
    Recruiting
    Last update posted :
    02/29/2024
    Initiation :
    02/28/2024
    Primary completion :
    12/30/2028
    Completion :
    12/30/2029
    EGFR • ALK
    |
    EGFR negative
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    Sacituzumab govitEcan in THYroid Cancers (SETHY) (NCT06235216)
    Phase 2
    Grupo Espanol de Tumores Neuroendocrinos
    Not yet recruiting
    Last update posted :
    01/31/2024
    Initiation :
    02/01/2024
    Primary completion :
    04/01/2027
    Completion :
    07/01/2027
    TACSTD2
    |
    Trodelvy (sacituzumab govitecan-hziy)
    Study of DF1001 in Patients With Advanced Solid Tumors (NCT04143711)
    Phase 1/2
    Dragonfly Therapeutics
    Recruiting
    Last update posted :
    01/29/2024
    Initiation :
    11/11/2019
    Primary completion :
    10/01/2026
    Completion :
    12/01/2026
    EGFR • ALK • ROS1
    |
    HER-2 positive • EGFR mutation • HR positive • HER-2 mutation • HER-2 expression • RET mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • DF1001